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Complement factor H (CFH) is the major regulator of the central complement protein C3b
in the alternative pathway of complement activation. A molecular view of the CFH interac-
tion with native heparan sulfate (HS) is central for understanding the mechanism of how
surface-bound CFH interacts with C3b bound to host cell surfaces. HS is composed of
sulfated heparin-like S-regions that alternate with desulfated NA-regions. Solution struc-
tural studies of heparin (equivalent to the S-regions) and desulfated HS (the NA-regions)
by scattering and ultracentrifugation showed that each structure was mostly extended
and partially bent, but with greater bending and flexibility in the NA-regions compared to
the S-regions. Their solution structures have been deposited in the Protein Data Bank.
The largest HS oligosaccharides showed more bent and flexible structures than those for
heparin. A folded-back domain structure for the solution structure of the 20 domains in
CFH was determined likewise. CFH binds to the S-regions but less so to the NA-regions
of HS. The bivalent interaction of CFH–heparin was observed by ultracentrifugation, and
binding studies of CFH fragments with heparin-coated sensor chips. In common with other
CFH interactions with its physiological and pathophysiological ligands, the CFH–heparin and
CFH–C3b interactions have moderate micromolar dissociation constants KD, meaning that
these complexes do not fully form in vivo. The combination of the solution structures and
binding studies indicated a two-site interaction model of CFH with heparin at cell surfaces.
By this, the bivalent binding of CFH to a cell surface is co-operative. Defective interac-
tions at either of the two independent CFH–heparin sites reduce the CFH interaction with
surface-bound C3b and lead to immune disorders.
Keywords: analytical ultracentrifugation, surface plasmon resonance, X-ray scattering, complement factor H,
heparin, heparan sulfate
INTRODUCTION
Complement is a major defense and clearance system of the innate
immune system (1, 2). Pathogens activate complement C3 through
one of three pathways, the classical, lectin, or alternative pathways.
Unactivated C3 consists of 13 domains, namely eight macroglob-
ulin domains, a linker domain, an anaphylatoxin domain (C3a)
a complement C1r/CIS–UEGF–BMP1 domain (CUB), a C345
domain, and a thioester domain (TED, also known as C3d). These
three pathways lead to the removal of the small C3a domain from
C3, the main complement protein, to convert this to C3b. Active
C3b is rapidly generated through a cascade and becomes covalently
attached to cell surfaces through its TED domain (Figure 1A).
This triggers the assembly of the membrane attack complex that
lyses pathogen cells and the clearance of C3b-opsonized cells by
phagocytosis. C3b formation needs regulation, because too much
C3b will damage host cells, while too little C3b means that the
host becomes immuno-compromised. Recent reviews refer to this
balance as a “double-edged sword” (3, 4). C3u is formed by the
Abbreviations: aHUS, atypical hemolytic uremic syndrome; AMD, age-related
macular degeneration; CFH, complement factor H; CUB, complement C1r/CIS–
UEGF–BMP1 domain of C3; K D, dissociation constant; SCR, short complement
regulator; TED, thioester domain of C3.
spontaneous hydrolysis of the thioester bridge in C3, but is no
longer able to bind to cell surfaces. The main C3b regulator is
complement factor H (CFH; Figure 1A), and CFH also binds to
C3u. Both C3 and CFH are relatively abundant complement pro-
teins in plasma. The most abundant plasma proteins are human
serum albumin (30–50 mg/ml) and the immunoglobulins (10–
15 mg/ml). In comparison, C3 is typically found at 1.0–1.6 mg/ml
(5.3–8.5µM), while CFH is almost equimolar to C3 at around
0.116–0.81 mg/ml (0.8–5.3µM). The large amounts of these com-
plement proteins compared to others, such as, for example, the
main coagulation proteins present at 0.1–10µg/ml (0.1–0.3 nM),
are attributable to the need for abundant reagents to combat infec-
tions. The uncontrolled release of C3b is regulated by CFH. Firstly,
CFH blocks the binding of complement Factor B to C3b and that
of its activated form Bb to C3b, the binding of which produces
the C3 convertase that cleaves C3 to produce even more C3b. Sec-
ondly, CFH acts as a cofactor of the protease Factor I that cleaves
C3b into the inert fragments C3d and C3c. CFH functions both in
plasma and by binding to host cell surfaces through interactions
with anionic oligosaccharides bearing clusters of negative charges.
Here, we summarize recent progress in our molecular under-
standing of how CFH binds to heparin and heparan sulfate (HS),
thereby protecting host cell surfaces. Firstly, we describe recent
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FIGURE 1 | Domain structure of factor H and its C3b and heparin
ligands. (A) Schematic view of the 20-SCR domains of CFH. The
positions of two C3b binding sites (SCR-1/4 with C3b decay acceleration
and factor I activity, and at SCR-19/20), two heparin-binding sites at SCR-7
and SCR-20, and two C3d-binding sites on each of SCR-19 and SCR-20
are shown schematically. The location of eight N -linked glycosylation sites
is shown by symbols; a ninth site at SCR-4 is not occupied. The 12
domains of C3b are shown to the left, with the TED domain (“thioester
domain”; equivalent to C3d) in red and the CUB domain (“complement
C1r/CIS–UEGF–BMP1”) in cyan. (B) Comparison of molecular views for
CFH with structures for its C3b and heparin dp36 ligands. All are on the
same scale. A folded-back domain arrangement of a best-fit CFH
structural model is shown with its longest length running from left to right
(SCR-1–SCR-20). The CFH structure is from two recent studies (27, 54).
The eight CFH oligosaccharides are shown in gray. The CUB and TED
domains are shown in cyan and red, respectively. The SCR-1/4 domains
are shown bound to C3b at the left (28). The folded-back central region of
CFH with the shorter and glycosylated SCR domains is shown to the
bottom right. Two solution structures of dp36 (blue) are shown proximate
to SCR-7 and SCR-19/20.
three-dimensional molecular structures for heparin and HS. Their
original structures came from a 1H NMR study of heparin and the
crystallography of small oligosaccharides bound to proteins. These
first structures have now been supplemented by the use of a power-
ful new method based on the modeling of X-ray scattering curves
and sedimentation coefficients that produced new structures for
the larger fragments of heparin and HS. Secondly, we summa-
rize the molecular structure for CFH. Intact CFH is comprised
of 20 short complement regulator (SCR) domains, each of length
about 61 residues, and joined together by linkers of lengths 3–8
residues (Figure 1A). Crystal and/or NMR structures are available
for over half the CFH SCR domains. Intact CFH has not been
crystallized to date, this being attributed to its comparatively large
size, its ability to dimerize in at least two sites, its sizeable gly-
cosylation in the center of CFH, and the potential flexibility of
the inter-domain linkers. Instead, X-ray scattering and sedimen-
tation coefficient modeling gave the first molecular structures for
full-length CFH (Figure 1B). Thirdly, we describe the complexes
formed between CFH and heparin. Again no crystal structures
for CFH–heparin complexes are known to date. The application
of analytical ultracentrifugation to the heparin complexes with
CFH revealed the existence of bivalent CFH–heparin complexes.
Binding experiments by surface plasmon resonance confirmed the
existence of these bivalent complexes, and importantly showed
that these complexes are formed co-operatively.
These structural advances have transformed our understand-
ing of the molecular basis of the interactions of CFH with
heparin and HS. They also provide new insight on the molecu-
lar mechanisms that lead to immune diseases such as age-related
macular degeneration (AMD) and atypical hemolytic uremic
syndrome (aHUS).
BIOPHYSICAL METHODS
We summarize for immunologists the biophysical methods used
for these studies. The joint use of three independent (or “orthog-
onal”) biophysical methods is a powerful means of characterizing
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the molecular interactions of heparin and HS with CFH. This
combination reduces the experimental uncertainties inherent in
the use of one method alone. For example, the dissociation con-
stants K D of an interaction can be obtained from all three methods
as a quantitative test of consistency. In addition, each method has
unique strengths.
(a) In analytical ultracentrifugation, sedimentation velocity
experiments subject the samples to high rotor speeds. These,
sediment to the bottom of the rotor cells at rates that depend
on the macromolecular shape and mass according to the Sved-
berg equation. Modern PCs record as many as several hun-
dred sedimentation boundaries during an experiment. The
resulting sedimentation coefficient distribution c(s) produces
peak(s) that correspond to the macromolecule(s) present in
the sample (see below). When complexes are studied, the
unbound and complexed species are revealed by separate
peaks (if slow exchange conditions are satisfied) that provide
the individual sedimentation coefficients s20,w (after correc-
tion to 20°C and the density of water) and their molecular
masses. The K D values are obtained from integration of the
c(s) peak areas (5). The s20,w values report on the shape
and can be compared directly with molecular models. The
main advantage of this method is the ability to resolve distinct
species.
(b) X-ray scattering measures the diffraction from macromole-
cules in random orientations in solution, from which the
overall dimensions of the solution structure can be deter-
mined. Dimensions are measured using the radius of gyration
RG values from Guinier plots and the lengths from distance
distribution P(r) analyses. If atomic structures are available
for modeling, such as the domains of a large multidomain pro-
tein, a molecular structure can be determined by constrained
modeling methods. By this, the known domain structure is
rearranged into thousands of possible allowed conformations,
then the best-fit molecular structure is identified by curve-
fitting. This is the main advantage of scattering. The resulting
structure is deposited in the Protein Data Bank as a permanent
record. If scattering is used for determining the K D value, this
requires knowledge of the scattering curves for the unbound
structures as well as for their complex (5). The ratio of the
unbound and complexed species is determined by scattering
curve fits measured at different concentrations, from which
the K D value is calculated.
(c) Surface plasmon resonance uses ligands or macromolecules
that are immobilized on a sensor chip. The on-rate and off-rate
of a soluble “analyte” binding to the immobilized interaction
partner (the “ligand”) are determined. If these rates are rela-
tively slow, the ratio of the off-rate/on-rate gives the K D value.
If these rates are relatively rapid, the overall intensity change of
the response when the analyte is bound to the ligand as a func-
tion of its concentration given an alternative determination of
the K D value (6). No shape information is available by this
method. However, a different sensor chip technology termed
dual polarization interferometry (data not shown) provides
both the K D value and the dimensions of the bound analyte
molecule.
SOLUTION STRUCTURES OF HEPARIN dp6–dp36
The disaccharide subunit (dp2) of heparin contains two residues
of uronic acid and d-glucosamine linked by a (1→ 4) glycosidic
bond (Figure 2A). The uronic acid can be either α-l-iduronic
acid (α-IdoA), which accounts for up to 90% of heparin, or β-
d-glucuronic acid (β-GlcA), which accounts for up to 10% of
heparin. A heparin disaccharide most often contains three sulfate
groups, one located on the 2-OH group of α-IdoA, and two at the
2-NH2 group and the 6-OH group of d-glucosamine (α-GlcNS),
namely [→4)-α-l-iduronic acid-(1→ 4)–α-d-glucosamine (2,6-
disulfate)-(1→]. This is abbreviated as IdoA2S–GlcNS6S. In fact,
heparin is most heterogenous (7). While the main structure is
the repeating tri-sulfated disaccharide IdoA2S–GlcNS6S, there are
four possible uronic acids in heparin, namely GlcA, GlcA2S, IdoA,
and IdoA2S, with the last one being the most common. There are
seven possible glucosamines, namely GlcNS, GlcNS6S, GlcNS3S,
GlcNS3S6S, GlcNAc, GlcNAc6S, and rarely glycosamine with a
free amine. The most common is GlcNS6S. The other disac-
charide in heparin is [→4)-β-d-glucuronic acid-(1→ 4)–α-d-N -
acetyl glucosamine-(1→], which is abbreviated as GlcA–GlcNAc.
The high degree of sulfation and carboxylation makes heparin
FIGURE 2 | Chemical structures of the two disaccharide repeats of
heparin and HS. (A) The major repeating disaccharide unit in heparin
(α-iduronic acid-2-sulfate→ α-glucosamine-2,6-disulfate; α-IdoA2S and
α-GlcNS6S). The molecular mass of this trisulfated disaccharide is 573 Da.
The ϕ angle between the rings is determined from the O5′–C1′–O4–C4
atoms and the ψ angle is determined from the C1′–O4–C4–C3 atoms,
indicated by two arrows. (B) The major repeating non-sulfated disaccharide
unit of HS (β-glucuronic acid→ α-N -acetylglucosamine; β-GlcA and
α-GlcNAc). The molecular mass of this averaged disaccharide is 378 Da.
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the most negatively charged macromolecule known in biology.
For experimental studies, the six fragments of heparin dp6–
dp36 were prepared from bovine lung heparin, starting from
heparinase-I-digested heparin, followed by Biogel P-10 prepara-
tive gel permeation chromatography to separate the individual
oligosaccharides (8).
Our ultracentrifugation and scattering fit procedure gave mol-
ecular structures for the six heparin fragments dp6–dp36. Confor-
mational information on the structure of heparin had previously
come from NMR studies of heparin dp12 and crystallography
studies of proteins co-crystallized with small heparin fragments
with sizes close to dp5. Our new structural analyses (8) proceeded
in three stages:
(a) First, using analytical ultracentrifugation, sedimentation
velocity runs were performed on each of the six heparin frag-
ments dp6–dp36. Single clean peaks were seen in the c(s)
analyses, indicating that the purifications gave satisfactorily
homogenous preparations. The six experimental sedimenta-
tion coefficients increased with size, ranging from 1.09 S for
dp6 to 1.84 S for dp36. Linear molecular models were created
for heparin dp10–dp40 starting from the NMR molecular
structure for heparin dp12. The sedimentation coefficients
s20,w calculated from these linear models agreed well with the
experimental values.
(b) Second, X-ray scattering curves with very good signal–noise
ratios were measured at the ESRF synchrotron, even for the
smallest heparin, dp6. This resulted because of the high beam
intensity, low scattering backgrounds, and improved detector
technology. Good linear Guinier analyses and distance distri-
bution curves resulted in RG values that increased from 1.03–
1.33 nm for heparin dp6 to 3.12–3.52 nm for heparin dp36.
The comparison with the linear heparin models showed that
the modeled RG values increased linearly with heparin size,
while the experimentally measured RG values for dp18–dp36
did not increase in proportion. Therefore, the experimental
RG values showed sensitivity to bending in the heparin struc-
tures with increase in size. Other scattering parameters (i.e.,
the cross-sectional RG values and the maximum dimensions)
also indicated that the larger heparin structures displayed
bending.
(c) Third, constrained atomistic modeling revealed the molecu-
lar structures of heparin dp6–dp36 that best fitted the X-ray
scattering curves. The major conformational determinant of
heparin are the two torsion angles ϕ and ψ of the glycosidic
linkage (Figure 2A), defined by the O5′–C1′–O4–C4 atoms
and the C1′–O4–C4–C3 atoms, respectively. Both torsion
angles were randomized in steps of up to ±45°. This process
generated 5,000 randomized heparin structures, starting from
a linear structure. Each randomized model was compared with
the experimental X-ray data by calculating the RG value of
each model and the goodness-of-fit R-factor of each curve
fit. The best-fit polysaccharide structures were determined
from V-shaped graphs of R-factors vs. RG values by identi-
fying the points with the lowest R-factors that showed the
best agreement with the experimental RG values (red circles;
Figure 3).
In conclusion, the best-fit molecular models for heparin
showed that their bending increased with heparin size (Figure 4).
This outcome extends the earliest NMR and crystallographic
results for the small heparin structures that suggested that they
were mostly linear. Our heparin dp6 and dp12 solution struc-
tures are mostly extended, but those for heparin dp18, dp24, dp30,
and dp36 are reduced in lengths by 16–29% compared to their
linear structures (Figure 5A). These bent models agree with the
ultracentrifugation s20,w values although the s20,w values are not
sensitive to conformational bending. The original models (8) have
been updated by removing minor steric overlaps between indi-
vidual atoms using a constant force field termed the DREIDING
minimization (9). They are available in the Protein Data Bank at
http://www.rcsb.org/pdb/ or after 2009 in PDB-formatted files in
the Supplementary Material of our publications. As far as is known,
the heparin study was the first successful application of atom-
istic scattering modeling to oligosaccharides, this method having
previously been used for multidomain proteins.
The best-fit models from varying only the ϕ and ψ angles
between the sugar rings were readily identified at the minima
in Figure 3. The quality of the dp18–dp36 scattering curve fits
is better than those found with many multidomain proteins
(Figure 4). From the fits, the solution ϕ andψ values were around
−60° and 130°, respectively, for the IdoA2S–GlcNS6S bond, and
around 100° and 85°, respectively, for the GlcNS6S–IdoA2S bond
(Figures 6A,B). Interestingly, comparisons with 19 crystal struc-
tures of heparin dp4–dp10 in protein complexes revealed similarϕ
andψ angles (Figures 6A,B). When the outliers were removed, the
crystallographic ϕ and ψ values were−79° and 132°, respectively,
for the IdoA2S–GlcNS6S bond, and 84° and 100°, respectively,
for the GlcNS6S–IdoA2S bond (Figures 6A,B). Given standard
deviations of typically ±20°, these ϕ and ψ values suggest that
the free heparin solution structures for dp18–dp36 is essentially
unchanged in conformation from small heparin fragments bound
to proteins in crystal structures. Thus, heparin in both its com-
plexes or free in solution has a semi-rigid and extended con-
formation that is optimal for binding to proteins without major
conformational changes.
The repulsion of the sulfate and carboxylate groups in heparin
may influence these extended structures. The anionic sulfate and
carboxylate groups of heparin form mostly ionic contacts with
basic amino acids on protein surfaces. The axial orientations of
these groups in heparin are thus crucial, and these repeat them-
selves after every four oligosaccharide rings. The dp4 fragment
possesses at least six sulfate groups and two carboxylate groups.
In dp4, two sulfate groups are located in opposed axial orienta-
tions in GlcNS6S, while the third sulfate and the carboxylate group
are located in opposed axial orientations in IdoA2S residues (8).
When crystal structures of dp3 fragments are viewed centered on
either IdoA2S or GlcNS6S, these axial orientations are largely pre-
served and aligned with each other between IdoA2S and GlcNS6S
residues (8). Our solution structures of heparin dp18–dp36 sug-
gest that these extended arrangements and orientations seen in
crystal structures are mostly preserved.
The larger heparin fragments show more pronounced bend-
ing, even though the mean ϕ and ψ angles are unaffected. The
scattering modeling represented this bending as occasional kinks
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FIGURE 3 | Constrained modeling analyses of heparin dp18–dp36.
(A) The R-factor values from the curve fits for 5,000 trial randomized models
of heparin dp18 are compared with their RG values. The vertical dashed line
corresponds to the observed experimental RG value. The red circle (arrowed)
denotes the best-fit model, and the green circle (arrowed) denotes the linear
model for heparin. Other best-fit models are shown in cyan close to the
R-factor minimum. Here and in Figures 4–6, the heparin structures are
corrected for minor steric overlaps (9). (B–D) The corresponding analyses for
each of the 5,000 trial models for heparin dp24, dp30, and dp36 are shown in
that order.
in the heparin structure. These bends may arise from the occa-
sional occurrence of GlcA–GlcNAc residues in the dominant
IdoA2S–GlcNS6S structure. It is more likely that kinks occur nat-
urally within the IdoA2S–GlcNS6S structures, these having been
observed in several protein–heparin crystal structures (8). Thus
the observation of bending indicates that heparin is not completely
rigid, and that limited flexibility in heparin is permitted.
The heparin structures clarify three different scenarios for
heparin–protein interactions. As far as is known, heparin binding
sites are generally found at surface-exposed positions in proteins.
One scenario involves two independent and different heparin
binding sites on the same protein, such as that in CFH. Because
heparin is semi-rigid and extended, it is unlikely that a single large
heparin molecule can undergo large conformational changes in
order to bind both CFH–heparin sites simultaneously to form a
1:1 complex, thus these two sites remain independent (10). In a
second scenario, heparin will mediate conformational changes in
proteins in order to induce functional activity. The best-known
case is that of antithrombin, in which the allosteric activation of
its β-sheet structure by heparin lead to the inhibition and reg-
ulation of the blood coagulation protein Factor IXa, Factor Xa,
and thrombin (11). A third scenario is the ability of heparin to
enable functionally active protein dimers to form through heparin
binding to single sites on each protein monomer [for example,
the fibroblast growth factor family and their receptors (12, 13)].
All three scenarios are facilitated by the semi-rigid and extended
structures of heparin.
SOLUTION STRUCTURES OF HEPARAN SULFATE dp6–dp24
Native HS plays key roles in the regulation of physiological
and pathophysiological processes. Native HS is comprised of the
same two alternating residues of uronic acid and d-glucosamine
residues as in heparin, but with a reduced degree of sulfation
(Figure 2B). HS contains a higher proportion of the GlcA–
GlcNAc disaccharide compared to the sulfated IdoA2S–GlcNS6S
disaccharide in heparin considered above.
The overall structure of native HS shows a distinct three-
domain organization that is comprised of short S-domains with
IdoA2S–GlcNS6S disaccharides, long NA-domains with GlcA–
GlcNAc disaccharides, and mixed domain regions at the junctions
between the S-domains and NA-domains that includes IdoA2S–
GlcNS6S disaccharides. The S-domains and mixed domain regions
occur as “hypervariable” regions that lead to different HS func-
tions when HS is purified from different cell types. The S-domains
correspond closely to heparin. For experimental studies of the
NA-domains, the non-sulfated HS oligosaccharide fragments dp6–
dp24 were prepared by digests, and this product is termed the
HS fragments below, unless specified otherwise. First, exhaus-
tive heparinase I digestion was used to minimize the content of
fully sulfated heparin sequences in a crude glycosaminoglycan
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FIGURE 4 | X-ray modeling curve fits for best-fit heparin dp18–dp36
models. (A–D) Correspond to the structural fits for heparin dp18, dp24,
dp30 and dp36. The experimental I(Q) and P (r ) X-ray scattering data are
represented by black circles or lines, respectively. The red lines and models
correspond to the best-fit dp18–dp36 models from the searches (Figure 3).
The maximum lengths of the models are shown for comparison with their L
values in the P (r ) curves.
mixture. This generated the NA-regions dp6-dp24 that remained
following the removal of sulphated oligosaccharides, then Bio-
gel P-10 preparative gel permeation chromatography was per-
formed to separate these individual GlcA–GlcNAc oligosaccha-
rides. The HS fragments dp6–dp24 were submitted to the same
ultracentrifugation–scattering-modeling strategy used above for
heparin.
Analytical ultracentrifugation on each of the HS fragments
dp6–dp24 revealed homogenous preparations from the single
peaks seen in the c(s) analyses. The experimental sedimentation
coefficients s20,w increased with HS size from 0.82–1.05 S for dp6
to 1.26–1.35 S for dp24 as expected. This time, their values were
generally reduced compared to the s20,w values for heparin dp6–
dp36. Most of this reduction comes from the lower masses of
HS dp6–dp24 compared to heparin dp6–dp24 (Figure 2). The
remaining reduction is attributable to a more compact solution
structure for the HS fragments compared to heparin, i.e., HS is
not as extended as heparin. Linear molecular models were created
for HS dp6–dp30 starting from a HS dp4 crystal structure. Again
the experimental s20,w values were lower than the predicted values
from the linear HS models, showing that HS does not have an
extended structure (14).
X-ray scattering curves for the HS fragments dp6–dp24 gave
RG values that increased from 0.98–1.03 nm for HS dp6 to 2.82–
3.00 nm for HS dp24. The comparison with the linear HS models
showed that the predicted RG values increased linearly with HS
size, while the experimental RG values starting from dp18 did not
increase by as much. Thus the experimental RG values also revealed
bending in the larger HS structures. Bending was also indicated
from the cross-sectional RG values and the distance distribution
curves P(r) (9, 14).
The constrained scattering modeling identified molecular
structures for the eight HS dp6–dp24 fragments. Totals of 5,000–
12,000 conformationally randomized structures were generated by
variations of the two torsion anglesϕ andψ. Each model was com-
pared one-by-one against the X-ray curve. For HS dp6–dp16, good
curve fits were obtained with almost linear structures with slight
bending (cf: Figure 4; not shown). Interestingly, the two largest
HS fragments dp18 and dp24 showed a different outcome. The R-
factor vs. RG graphs (cf: Figure 3; not shown) for dp18 and dp24
showed that the modeled RG value at the minimum R-factor was
different from the experimental RG value. The smaller modeled
RG value of 2.13 nm (dp18) and 2.47 nm (dp24) suggested that
the HS structures were noticeably bent, while the larger experi-
mental RG value of 2.34 nm (dp18) and 2.82 nm (dp24) suggested
that the HS structures were mostly extended. The modeled s20,w
values for both the bent and extended structures were the same
within error. This outcome suggested that conformational hetero-
geneity was present in HS, and that each of HS dp18 and dp24
exhibited both bent and extended structures simultaneously in
solution (Figure 5B).
The organization of sulfated heparin-like S-domains and
unsulfated NA-domains in the HS structure has been clarified
by our work. The comparison of our heparin and HS structures
becomes essentially that between S-domains and NA-domains
(Figure 5). The greater bending and flexibility of HS compared
to heparin is attributable to the GlcA–GlcNAc disaccharides in HS
and the IdoA2S–GlcNS6S disaccharides in heparin. The available
crystal structures show that the separations between the rings in
GlcA–GlcNAc and IdoA2S–GlcNS6S are similar. Thus the differ-
ent heparin and HS conformations must result from altered ϕ and
ψ angles. The ϕ and ψ angles for heparin dp18–dp36 in solution
are within 18° of those in 19 crystal structures (Figures 6A,B).
The ϕ and ψ angles for HS dp6–dp24 in solution were all within
5° of those in the HS dp4 crystal structure (Figures 6C,D). While
not significantly larger than the standard deviations, the largest
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FIGURE 5 | Superimposition of the best-fit models for heparin and HS.
(A) The nine best-fit models for each of the four heparin fragments
dp18–dp36 were superimposed. Only the non-hydrogen atoms are
displayed. The best-fit model is shown in red, while the others are shown in
cyan. The overall lengths of heparin dp18 and dp24 are shown as 7.0 and
9.0 nm, as arrowed. (B) Each set of eight best-fit models for the two HS
fragments dp18 and dp24 were superimposed. The best-fit model is shown
in red, while the others are shown in green. The overall lengths of the
extended HS dp18 and dp24 models were shown as 8.5 and 10.0 nm, as
arrowed. The extended best-fit HS structures were obtained primarily from
filtering on the RG values, while the bent best-fit structures were identified
by filtering on the R-factor values only.
differences between heparin and HS involve the twoϕ angles rather
than the two ψ angles. The physical basis for this is most likely
to arise from the IdoA2S–GlcNS6S sequences in heparin com-
pared to the GlcA–GlcNAc sequences in HS. Unlike HS, heparin
will be influenced by greater repulsions between pairs of sulfate–
sulfate, sulfate–carboxylate, and carboxylate–carboxylate groups.
Thus, the combination of the NA- and S-domains within native
HS suggests that different native HS structures with greater or
lesser bending may arise through variations of the sizes of the
NA-domains and S-domains. For example, a three-part native HS
structure comprised of a NA-region at its center and flanked by
two S-regions would show conformational flexibility in its central
region and influence its immune reactivity.
An important caveat in these molecular studies should be
noted. When we first published our HS best-fit structures (15),
the anomeric configurations of GlcA and GlcNAc in our HS struc-
tures should have alternated between α and β. Unfortunately, the
anomeric configurations were all β in our original HS models, thus
our original study was withdrawn. The HS structures were remod-
eled with the correct anomers and republished (14). Although we
take full responsibility for our mistake, the error was traced back
to a misunderstanding of the starting HS dp4 structure in the Pro-
tein Data Bank. That HS dp4 structure was written out with its
reducing end at the left, when it is more conventional to write this
at the right end. In addition, terminological inconsistencies exist
in the Protein Data Bank that contributed to our misunderstand-
ing. For example, theα-GlcNAc and β-GlcA anomers of HS should
have been written as NDG and BDP, respectively, in the HS dp4
crystal structure, and not as NAG and GCU (PDB code 3E7J; dated
18 August 2008). Related discrepancies in carbohydrate structures
have been reported by others (16, 17). It appears essential to check
carbohydrate structures from the Protein Data Bank before using
these in molecular modeling.
LIGAND INTERACTIONS OF COMPLEMENT FACTOR H
We first summarize the immune functions of CFH. The 20-SCR
domains of CFH perform several functions by binding to various
ligands. The major N-terminal and C-terminal binding sites for
complement C3b in CFH are located at SCR-1/4 and SCR-19/20,
and the C3d fragment of C3b binds to SCR-19/20 (Figure 1A)
(18). A third C3b binding site specific for C3c has been proposed
in the central part of CFH (18–20). These interactions lead to the
regulatory breakdown of C3b by CFH. The two heparin binding
sites of CFH are located close to SCR-6/8 and SCR-19/20 (18).
These sites enable the binding of CFH to host cell surfaces, but
not to the surfaces of pathogens, thus leading to the complement
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FIGURE 6 | Phi (ϕ) and psi (ψ) dihedral angles for heparin and HS. The
four atoms that define the ϕ and ψ dihedral angles are shown in Figure 2.
(A,B) For heparin, the IdoA2S–GlcNS6S and GlcNS6S–IdoA2S ϕ–ψ angle
pairs from the best-fit solution structure models are shown as filled circles
for each of dp18, dp24, dp30, and dp36. Their mean values are shown in red
(9). The ϕ–ψ pairs from the corresponding crystal structures are shown in
blue. (C,D) For HS, the GlcA–GlcNAc and GlcNAc–GlcA ϕ–ψ angles in the
best-fit models for each fragment are shown. These correspond to
structures for dp6 to dp24, and their mean values are shown in red (14).
regulatory protection of host cells. CFH also binds C-reactive
protein at SCR-6/8 and SCR-16/20 (6). The binding of C-reactive
protein to damaged host cells will lead to C3b regulation follow-
ing CFH binding to C-reactive protein. Weak zinc binding sites
are primarily located within SCR-6/8 (21); these sites lead to the
precipitation of CFH–C3b complexes in the pathophysiological
concentrations of zinc found in the retina (22). In addition to
these ligand interactions, CFH self-associates with itself to form
dimers and higher oligomers (23). Although the physiological role
of CFH oligomers is not yet clear, except perhaps in facilitating the
development of drusen deposits in the retina at the onset of AMD
(23), CFH oligomer formation is a significant factor in the design
of experiments with CFH.
For immune function, the four most notable features of
CFH–ligand interactions are their moderate binding strengths,
their multivalency, their dependence on ionic strength, and CFH
self-association:
(i) The strength of the CFH–ligand interaction is central for
complement regulation. For most macromolecular interac-
tions, the dissociation constant K D is similar to the physiolog-
ical concentration. The K D corresponds to the concentration
at which a given complex is 50% dissociated. Given that
C3 and CFH occur at 2–7µM levels in plasma, the first
compilation of all the CFH–ligand K D values (24) unsur-
prisingly showed that most K D values are also micromolar.
These micromolar values mean that only partial complexes of
CFH with C3b and heparin are formed during normal CFH
regulatory function. In addition, these micromolar affinities
mean that these CFH–ligand interactions can be easily mis-
interpreted in biochemical assays for reason of incomplete
binding.
(ii) Complement factor H undergoes multivalent interactions
with its major C3b, C3d, heparin, and CRP ligands. Multi-
valency means that analyses based on simple 1:1 interactions
may not be adequate for accurate quantitative studies of
the CFH–ligand interaction. This issue is best resolved by
performing CFH fragments–ligand studies alongside studies
based on full-length CFH, such as those of CFH with heparin
to characterize its co-operative binding (10).
(iii) Many CFH–ligand interactions involve opposing ionic inter-
actions between CFH and its ligands. The buffer in plasma
corresponds to 137 mM NaCl/11 mM phosphate (24). Exper-
iments that use low salt will promote these interactions, while
high salt will inhibit these interactions. While the use of low
(50 mM NaCl) and high (250 mM NaCl) salt levels can be
useful, they may lead to undesired side-effects. For example,
C3d is monomeric in 137 mM NaCl, yet forms dimers and
trimer/tetramer in 50 mM NaCl buffer (25). A related case
is 2 mM calcium that stabilizes C-reactive protein, thus the
use of 2 mM calcium is important for its binding studies with
CFH (6).
(iv) Full-length CFH is well-characterized to undergo 5–14% self-
association in 137 mM NaCl/11 mM phosphate buffer. The
presence of CFH oligomers will complicate experiments that
require high protein concentrations.
BIVALENT AND CO-OPERATIVE BINDING OF CFH–HS
The immune function of CFH is determined by its major func-
tional activities at its N-terminal and C-terminal SCR domains
(Figure 1). The middle SCR domains possess shorter sequences,
longer inter-domain links, and higher glycosylation levels, sug-
gesting that these middle domains act as conformational spacers.
Because there is no crystal structure for full-length CFH, the
combination of X-ray and neutron scattering and sedimenta-
tion coefficient modeling produced the first molecular structures
for full-length CFH (26, 27). The CFH structure determination
approach is similar to those for heparin and HS fragments above.
The scattering modeling was based on molecular structures for
all 20-SCR domains. These were taken directly from crystal or
NMR structures for small CFH fragments, or from predicted SCR
structures by homology modeling based on the closest match with
known crystal or NMR structures. The inter-SCR linkers are vari-
able and not predictable in their conformation. For the scattering
modeling, these linkers were conformationally randomized and
used to assemble 2,000 SCR models for CFH in randomized ori-
entations. The scattering curve fits showed that only folded-back
domain structures with an overall length of 40 nm (Figure 1B) fit-
ted the CFH scattering data. Its length is much reduced compared
to a hypothetical linear structure for CFH, which would be 73 nm
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in length. Two distinct models for CFH have been computed,
which give similar and indistinguishable scattering fits. In the first
one, the SCR-1/7 domains are extended in shape and SCR-8/20
are looped back (Figure 1) (24). In the second one, the SCR-13/20
domains are extended and SCR-1/12 are looped back (27). The first
model is more easily docked with the C3b–CFH crystal structure,
because this requires SCR-1/4 to be extended in shape (28).
The CFH–HS interaction forms the basis for the protection
of the native HS-coated host cell surfaces via the S-domains
of HS from attack by the innate immune system, directing this
immune response instead against pathogenic bacteria, which lack
a polyanionic oligosaccharide coating and are therefore unpro-
tected by CFH. Polyanionic molecules such as HS and others such
as the sialic acids on host cell surfaces enhance the regulatory
effectiveness of CFH by 10-fold through its inhibition of com-
plement activation (29–31). Two independent heparin binding
sites are located at the SCR-6/8 and SCR-19/20 domains in CFH
(Figure 1A). Notably, SCR-7 and SCR-20 have the two most basic
charge densities in CFH (27), these basic charges being optimal
for interactions with anionic S-domains. The availability of mole-
cular structures for CFH, heparin, and HS fragments (above), and
the combined application of ultracentrifugation, scattering, mol-
ecular modeling, and surface plasmon resonance (below) to study
CFH–heparin complexes provided the first molecular picture of
CFH binding to heparin.
The ultracentrifugation experiments of CFH mixtures with
heparin dp6–dp36 (equivalent to S-domains) identified multiple
different CFH–heparin complexes in the size distribution analy-
ses c(s) (10). Unbound monomeric CFH shows a peak close to
5.5 S. The peaks for heparin dp6–dp36 are between 1.1 and 1.8 S
and do not overlap with that for CFH. Even though unbound
CFH showed small oligomer peaks between 8 and 16 S that make
up 15% of the total peak intensity, the marked differences in
these peaks after adding heparin provided unequivocal evidence
of complex formation (Figure 7). The CFH mixtures with dp6
and dp12 showed small decreases in these peaks between 8 and
16 S (not shown). However the CFH mixtures with dp18–dp36
showed large peak intensity increases of up to 63% for dp36. If
CFH and heparin dp30/dp36 formed a 1:1 complex, the increased
peak sizes corresponded to a K D value of about 0.5µM. Even
with 63% CFH–heparin oligomer formation, the CFH monomer
peak continued to be visible, showing that complex formation is
incomplete. Ultracentrifugation also showed that heparin dp10
bound tightly to SCR-6/8 and this is consistent with a micromolar
affinity (32). In addition, the small CFH oligomer peaks shifted
to lower S values after adding heparin (Figure 7). This showed
that a new type of CFH oligomer structure with more extended
structures had formed with heparin. As controls, experiments with
native HS material (containing both S-domains and NA-domains)
showed similar peak changes, while the use of NA-domains alone
showed much reduced interactions with CFH.
The scattering experiments were complementary to ultracen-
trifugation because of their sensitivity to aggregate formation that
may be missed in the ultracentrifuge. In agreement with ultracen-
trifugation, little changes were seen by scattering for CFH mixtures
with heparin dp6 and dp12 (10). However, large increases in both
molecular weights and RG values were seen for CFH mixtures
FIGURE 7 | Sedimentation velocity analyses of CFH mixtures with
heparin dp30. CFH was studied alone (red) and with a 1:1 molar ratio of
dp30 (blue) by sedimentation velocity in the analytical ultracentrifuge. The
CFH monomer s20,w peak is labeled as 1, and the CFH oligomer s20,w peaks
for the dimer, trimer, and tetramer onward are denoted by 2, 3, 4, and
upwards. Peaks 2, 3, and 4 are better defined and the change in the
sedimentation coefficients between CFH and CFH–dp30 is shown by the
vertical dashed lines. On the right, dimer, trimer, and tetramer models for
CFH are shown in blue–green, with the heparin cross-links shown in red.
The dp30 heparin sizes are sufficiently long enough to cross-link the SCR-7
and SCR-20 domains between different CFH molecules, leading to the
formation of dimer, trimer, and tetramer as ring-like molecular structures.
Redrawn from Khan et al. (10).
with heparin dp18–dp36. The distance distribution analyses P(r)
showed that the maximum dimension of CFH increased from 34
to 40 nm in the presence of heparin dp36. Because no indefinitely
sized aggregates were seen by scattering, these results agree with
the formation of large CFH–heparin oligomers with specific sizes.
To clarify the ultracentrifugation and scattering results, sur-
face plasmon resonance experiments were performed with both
full-length CFH and recombinant SCR-6/8 and SCR-16/20 in solu-
tion with heparin immobilized on the sensor chip. The binding
data showed mostly fast on-rates and off-rates with the heparin
surface. Curve fits of the binding responses gave K D values of
1–3µM for full-length CFH, and similar but significantly weaker
K D values of 4µM for the SCR-6/8 fragment and 20µM for the
SCR-16/20 fragment (Figure 8). These K D values confirm coop-
erativity between the two different heparin binding sites in CFH.
As controls, the use of immobilized unfractionated HS contain-
ing both NA-domains and S-domains showed a K D value of 2µM
with full-length CFH, while use of immobilized HS fragments (i.e.,
NA-domains) showed much weaker CFH binding. These exper-
iments confirmed the importance of the heparin-like S-domains
for this interaction.
These methods show that the immune function of CFH at
host cell surfaces is well-described by a bivalent and co-operative
model of CFH binding to the S-domains of HS. To visualize this
model, molecular modeling of the ultracentrifugation s20,w data
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FIGURE 8 | Surface plasmon resonance of the CFH interaction with
heparin and HS. The binding curve fits used to determine the K D values are
shown for four experiments using immobilized heparin over which the CFH
samples were flowed. Redrawn from Khan et al. (10). (A) Biotinylated heparin
dp32 was immobilized on a streptavidin chip, and studied using plasma CFH to
give a K D value of 2.7µM. (B) CFH SCR-16/20 was used with the same dp32
chip, from which the K D value was determined as 20µM. (C) CFH SCR-6/8
was used with the same dp32 chip, from which the K D value was determined
as 4.3µM. (D) Biotinylated unfractionated HS was immobilized on a
streptavidin chip, and studied using plasma CFH to give a K D value of 2.3µM.
was performed. In the folded-back CFH solution scattering model
(Figure 1B), the heparin binding SCR-7 and SCR-20 domains were
separated by 26 nm. In contrast, the best-fit slightly bent heparin
dp36 model is only 12 nm long. Thus, heparin dp36 is not long
enough to cross-link the two heparin binding SCR domains in a
single CFH molecule. If however the SCR-7 and SCR-20 domains
in different CFH molecules were daisy-chained in alternation with
heparin dp36, ring-like models for dimers, trimers, tetramers, and
pentamers of CFH with heparin could be created (Figure 7). These
CFH–heparin models explained the experimental s20,w values for
the oligomer peaks (10) within an acceptable error of ±0.2 S
(blue; Figure 7). Either of the two distinct models for CFH (see
above) may be used to create these ring-like models. The modeling
therefore explained the changes in the peak positions after adding
heparin dp36. The modeling also explained why dp6 and dp12 did
not form oligomers with CFH, i.e., because they were too short to
cross-link CFH.
Complement factor H flexibility at its central domains is
unlikely to play a role in heparin binding. Our experimental
data for the heparin/HS fragments and CFH indicate that nei-
ther possesses sufficient flexibility to form one-to-one complexes.
No increased s20,w value for the CFH monomer was seen that
would indicate that CFH underwent a significant compaction in
the presence of heparin (apart from relatively low changes caused
by the increased mass of the CFH–heparin complex). This lack
of CFH flexibility concurs with the little conformational variation
seen in CFH with change in salt or pH (27). It is likely that the
heavily glycosylated and smaller SCR-12/15 domains at the center
of CFH maintain the structural independence of its N-terminal
and C-terminal ends. The presence of these two different heparin
sites at opposite sides of the CFH central region enables CFH to
bind selectively, bivalently, and co-operatively to host cells showing
a sufficient density of polyanions at their surfaces.
Flexibility in native HS is defined by the presence of semi-
rigid S-domains and flexible NA-domains that were deduced
from the scattering analyses. Our binding studies show that CFH
binds to heparin-like S-domains, but less so to the non-sulfated
NA-domains. If the parent HS structure shows flexibility at the
NA-domains, this would enable the individual S-domains to reori-
entate themselves to optimize their stronger contacts with CFH.
Thus CFH interacts in the same way with native HS as many other
proteins do that bind to native HS through the S-domains (33).
The quantification of the CFH–HS interaction permits critical
comparisons with other CFH–ligand affinities. The first full set
of K D values for CFH–ligand complexes was compiled recently
(24). This summary (Table 1) currently shows that the strongest
CFH interactions involve heparin and C3b/C3u. The affinity of
CFH (concentrations of 2–5µM in plasma) for heparin is around
1–2µM, with the CFH binding for heparin being bivalent. These
micromolar K D values mean that the CFH–heparin complexes
will not be fully formed in plasma, and the free and bound forms
will be in equilibrium with each other (footnote, Table 1). The
larger K D values of 4 and 20µM for the separate SCR-6/8 and
SCR-16/20 fragments correspond to weaker binding to heparin at
each of two independent binding sites (10). In comparison with
the K D value for intact CFH, this shows co-operative binding. The
CFH interactions with C3b and C3u have low K D values of around
1µM. Since C3 is 5µM in plasma, these complexes (Figure 9A)
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Table 1 | Selected dissociation constants, KD, for the CFH interactions with its ligands.
Interaction KD (µM)a Methodb Buffer (abbreviated)c Reference
CFH–HEPARIN
CFH–heparin dp32/dp36 0.5, 2.7 SV, SPR 10 mM HEPES with 137 mM NaCl, pH 7.4 (10)
SCR-6/8–heparin dp32 4.3 SPR 10 mM HEPES with 137 mM NaCl, pH 7.4 (10)
SCR-16/20–heparin dp32 20 SPR 10 mM HEPES with 137 mM NaCl, pH 7.4 (10)
CFH–C3b OR CFH–C3u
CFH–C3b 0.59–1.6 SPR 10 mM HEPES with 150 mM NaCl, pH 7.4 (18)
CFH–C3u 0.59 SV PBS with 137 mM NaCl, pH 7.4 (34)
SCR-1/4–C3b 11 SPR PBS with 150 mM NaCl, pH 7.4 (28)
SCR-1/4–C3b 9.8–13.5 SPR 10 mM HEPES with 150 mM NaCl, pH 7.4 (18)
SCR-19/20–C3b 5.4 SPR PBS with 140 mM NaCl, pH 7.3 (20)
SCR-19/20–C3b 3.5–4.5 SPR 10 mM HEPES with 150 mM NaCl, pH 7.4 (18)
SCR-19/20–C3b 0.54 SPR 10 mM HEPES with 150 mM NaCl, pH 7.2 (35)
CFH–CRP
CFH–CRP 4.2 SPR 10 mM Tris, 137 mM NaCl, 2 mM CaCl2, pH 7.4 (6)
CFH SELF-ASSOCIATION
CFH–CFH 28 SE 10 mM HEPES with 137 mM NaCl and EDTA, pH 7.4 (23)
CFH–ZINC
CFH–zinc ~10 SAXS 10 mM HEPES, 137 mM NaCl, pH 7.4 (21, 23)
C3b–zinc ~100 SAXS 10 mM HEPES, 137 mM NaCl, pH 7.4 (22)
aIf the interacting species are both at 5µM and the KD value is 1µM, 64% of the complex will be formed. If the KD value is 10-fold weaker at 10µM, 27% of the
complex will be formed.
bED, equilibrium dialysis; SAXS, small-angle X-ray scattering; SE, sedimentation equilibrium; SPR, surface plasmon resonance; SV, sedimentation velocity.
cBuffer additives are common, especially for SPR studies. These are reported in the more detailed survey of Perkins et al. (24).
will again be only partially formed in plasma. The K D values of
around 10 and around 4µM for the separate SCR-1/4 and SCR-
19/20 sites for C3b, respectively, are also weaker (18). The reason
why the latter two K D values are weaker compared to intact CFH
is not clear, because it has not been shown experimentally that
CFH binds bivalently to one molecule of C3b or C3u. A CFH–C3b
complex formed through SCR-1/4 binding (Figure 1B) may also
bind to a second molecule of C3b at its C3d (TED) domain, hence
decreasing the observed K D value (Figure 1A). Overall, however,
the similar binding affinities of CFH for C3b/C3u and heparin
indicate that these values are optimal for the effective immune
role of CFH as a host cell surface regulator of C3b activity.
The other CFH–ligand interactions are weaker than those of
CFH–heparin. C3d (K D of 3–8µM) and C-reactive protein (K D
of 4µM) (6, 36) show weaker affinities for CFH (Table 1), suggest-
ing that these interactions only become important during excess
inflammation (acute phase response) when high local concentra-
tions of C3d or C-reactive protein may occur. When either of
these two ligands is bound to host cell surfaces, additional CFH
binding sites are potentially available to reinforce host cell protec-
tion, similar to that suggested for CFH–heparin (Figure 9B). The
monomer–dimer K D value of 28µM for CFH self-association (23)
and the K D value of about 10µM for CFH–zinc binding and about
100µM for C3b–zinc binding indicate even weaker affinities (22).
The latter interactions are more relevant to drusen formation (reti-
nal deposits of aggregated proteins and oxidized lipids associated
with AMD) (37) than to the CFH–heparin interaction at host cell
surfaces.
Other groups have reported K D values for the CFH–heparin
interaction. That of 9.2 nM was reported for CFH binding to
unfractionated heparin in 50 mM Na phosphate, 100 mM NaCl
buffer, pH 7.2, while that of 9µM was reported for CFH SCR-
19/20 binding to heparin dp4 in 20 mM acetate, 200 mM NaCl
buffer, pH 4 (38, 39). The differences from the values in Table 1 are
attributable to the less physiological ionic strengths used in these
experiments, these buffers being rather different from that of Dul-
becco’s phosphate buffer (137 mM NaCl and 11 mM phosphate,
pH 7.4).
CONCLUSION AND FUTURE CONSIDERATIONS
The immune significance of the CFH–HS interactions has been
clarified by our molecular solution structures for heparin, HS,
and CFH. We provide a first molecular model of the CFH–HS
interaction, i.e., a bivalent and co-operative CFH binding mech-
anism to heparin and HS exists that clarifies how CFH binds to
host cell surfaces. At the cell surface, native HS is comprised of
sulfated heparin-like S-domains interspaced by desulfated NA-
domains of HS. The heparin solution structures possess semi-rigid
extended conformations with notably less flexibility than those
found in the flexible extended or bent desulfated HS structures.
The solution structure of CFH revealed a folded-back 20-SCR
domain structure in which the functional N-terminal and C-
terminal domains are extended outwards from a compact core of
shorter glycosylated SCR domains with longer inter-SCR linkers.
Unlike the NA-domains of HS, there is no evidence for significant
flexibility in full-length CFH. Consequently, the combination of
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FIGURE 9 | Schematic views of CFH binding to a host cell surface.
(A) CFH is represented by a cartoon showing the 20-SCR domains, and
bound to C3b in the cleft formed between the CUB/TED domains (blue–red)
and the macroglobulin, C345, and linker domains (yellow). A molecular view
of this interaction is shown on the right. (B) CFH binds bivalently at its
SCR-7 and SCR-20 domains to anionic charges on the HS-coated host cell
surface (denoted as HS and represented here by heparin dp36). For
simplicity, the C-terminal interaction of CFH with C3d (Figure 1A) is not
shown. This bivalent binding positions the SCR-1/4 domains in a
conformation that binds readily to C3b when C3b is covalently bound to
host cell surfaces through the thioester bond. The C3b interaction with CFH
results in the Factor I-mediated degradation of C3b to form C3d (the TED
domain) and C3c, thereby regulating complement activation at host cell
surfaces. (C) The potential effect of polymorphisms and mutations on C3b
regulation is schematically indicated. In AMD, the association of the
Tyr402His polymorphism in SCR-7 is presumed to weaken the interaction
between HS and SCR-7, so the proximity of CFH in relation to SCR-1/4 of
surface-bound C3b is reduced. In aHUS, mutations in SCR-19 and SCR-20
are presumed to weaken the interaction between HS and SCR-19/20, while
CFH remains bound to HS through SCR-7. In both AMD and aHUS, the
effect is that CFH is no longer held in an optimal position on the host cell
surface to interact with C3b at the SCR-1/4 domains.
the non-flexible CFH and heparin dp18–dp36 structures in vitro
leads to the formation of ring-like models for their complexes
(Figure 7). In vivo, the views of Figure 7 are readily transformed to
suggest how a CFH monomer binds to two different S-domains on
a host cell surface (Figure 9B). The flexibility of the NA-domains
may facilitate optimal binding of the CFH and S-domains at the
cell surface.
Such a bivalent CFH binding mechanism to HS has implica-
tions for immune function. In theory, the combination of two
separate weak binding events with micromolar affinities becomes
a much strengthened interaction if both weakly bound CFH sites
bind simultaneously to HS at a cell surface. This prediction was
confirmed by surface plasmon resonance studies of full-length
CFH and its functional fragments to immobilized heparin on sen-
sor chips. Such a binding interaction may position CFH SCR-1/4
away from the cell surface to facilitate their binding to surface-
bound C3b for its regulation. The binding of CFH at SCR-19/20
to the cell surface may orientate CFH into a position that is optimal
for its SCR-1/4 domains to bind to C3b (Figure 9B).
For reason of co-operativity, CFH is envisaged to bind pref-
erentially to surfaces showing the right spatial density of anionic
oligosaccharides. This implies that the moderately strong bind-
ing of CFH to host cell surfaces may differ between different
cell types or degrees of sulfation. If HS binding is reduced at
either SCR-7 or SCR-20 in CFH, co-operativity implies that there
will be a disproportionate effect on CFH regulatory function. In
CFH-associated genetic diseases such as AMD and aHUS, the
CFH–heparin interaction may be affected by polymorphisms or
mutations. Disease-risk polymorphisms will exert their effect over
a period of decades, while disease-causing mutations will show a
much earlier effect during a lifespan. The AMD-risk CFH poly-
morphism Y402H occurs in 33% of individuals. AMD occurs
primarily in the aged population, this being responsible for over
50% of blindness in the elderly in the Western world (40). Muta-
tions leading to aHUS occur mostly in the C-terminal SCR-19/20
domains of CFH, and aHUS is a common cause of renal failure in
young children (41).
The biochemical mechanism of CFH-associated genetic disease
may involve either the facilitation of CFH aggregation to form
pathogenic deposits, or the biochemical loss of CFH regulatory
control (42). Present evidence for either mechanism is not defini-
tive. In terms of an aggregation mechanism, CFH has been found
in drusen that are a hall-mark of AMD (43). Glycosaminoglycans
have also been identified within Bruch’s membrane, although their
size and structure in drusen is not yet known (44). The availability
of free S-domains in glycosaminoglycans with size dp18 or more
may lead to the formation of ring-like CFH–heparin aggregates,
e.g., if these S-domains are released from the cell surface during
inflammatory attack. Polyanions also cause CFH to aggregate (45).
In terms of an alternative mechanism based on reduced inflam-
matory regulation that may lead to disease, CFH disease-causing
mutations have been summarized on the web (46). These affect
each of the two CFH–heparin binding sites:
(i) Three studies of the Tyr402His polymorphism in SCR-7 show
that CFH His402 binds more weakly to heparin than CFH
Tyr402 (47–49). If so, the weaker binding of CFH His402 to
the heparin-like S-domains of HS would compromise both
the CFH interaction with C3b and the bivalent binding of
CFH to cell surfaces (Figure 9C). This scenario is similar to
that proposed for the CFH–CRP interaction (6) in that the
weaker binding of CFH His402 to host cell surfaces would
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predispose toward greater inflammatory damage. However,
other studies reported variable outcomes depending on the
heparin preparation in use and its degree of sulfation (50,
51), while another study reported that no significant differ-
ence was observable between the Tyr402 and His402 allotypes
(52). In opposition to these results, the crystal structure of
SCR-6/8 His402 bound to a heparin analog suggests that the
S-domains bind more strongly to the His402 allotype than to
the Tyr402 allotype (53).
(ii) For C-terminal CFH mutations in SCR-19/20 that lead to
aHUS, these occur mostly in young individuals, often being
triggered by an immune insult to the kidney such as a bac-
terial infection (41). aHUS is primarily caused by mutations
within SCR-19/20, often those affecting heparin binding or
C3d-binding properties (46). The C-terminal mutations may
affect CFH function by perturbing the orientation of SCR-
1/4 relative to C3b when CFH is bound to the host cell surface
(Figure 9C).
It is not clear at present why a polymorphism at SCR-7 in
CFH leads to one immune disease, while mutations at SCR-19/20
lead to a different disease altogether. Further developments to elu-
cidate the molecular mechanism for CFH binding to native HS
may lead to new therapeutic approaches for diseases such as AMD
or aHUS.
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